Frankfurt - Delayed Quote EUR

SynBiotic SE (SBX.F)

Compare
5.30 -0.02 (-0.38%)
As of 9:15:02 AM GMT+1. Market Open.
Loading Chart for SBX.F
DELL
  • Previous Close 5.32
  • Open 5.28
  • Bid 5.22 x --
  • Ask 5.26 x --
  • Day's Range 5.28 - 5.30
  • 52 Week Range 2.88 - 19.30
  • Volume 797
  • Avg. Volume 217
  • Market Cap (intraday) 29.678M
  • Beta (5Y Monthly) 4.49
  • PE Ratio (TTM) --
  • EPS (TTM) -2.24
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

SynBiotic SE engages in the research and development, production, and marketing of cannabinoid and terpene-based solutions to for pain, sleep deprivation, and anxiety. It also offers hemp, cannabinoids, dietary supplements, and cosmetic products; medical cannabis products; and cannabis products for recreational use under the Hempamed, Princess Stardust, The Hempany, and Hempamed Rx brand names. The company was formerly known as Ledgertech SE and changed its name to SynBiotic SE. SynBiotic SE was founded in 2015 and is based in Munich, Germany.

www.synbiotic.com

55

Full Time Employees

December 31

Fiscal Year Ends

Recent News: SBX.F

View More

Performance Overview: SBX.F

Trailing total returns as of 12/17/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

SBX.F
70.97%
DAX P
21.32%

1-Year Return

SBX.F
79.66%
DAX P
21.33%

3-Year Return

SBX.F
81.48%
DAX P
29.98%

5-Year Return

SBX.F
72.86%
DAX P
51.58%

Compare To: SBX.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: SBX.F

View More

Valuation Measures

Annual
As of 12/13/2024
  • Market Cap

    29.90M

  • Enterprise Value

    30.79M

  • Trailing P/E

    --

  • Forward P/E

    270.27

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    6.59

  • Price/Book (mrq)

    1.90

  • Enterprise Value/Revenue

    7.97

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -275.31%

  • Return on Assets (ttm)

    -13.92%

  • Return on Equity (ttm)

    -61.58%

  • Revenue (ttm)

    3.86M

  • Net Income Avi to Common (ttm)

    -10.63M

  • Diluted EPS (ttm)

    -2.24

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    --

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -78.21k

Research Analysis: SBX.F

View More

Company Insights: SBX.F

Research Reports: SBX.F

View More

People Also Watch